Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MC0518 vs Best Available Therapy for Steroid-Refractory Acute GvHD
NCT04629833Phase 3Recruiting
- Sponsor
- medac GmbH
- Start
- Aug 2021
- Primary completion
- Aug 2027
- Modality
- Stem Cell Therapies
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of mesenchymal stromal cells, ex vivo cultured in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by medac GmbH. Primary endpoints: Overall Response Rate at Day 28 and Overall Survival at Month 24. Started Aug 2021; status: recruiting.
02
Drugs
mesenchymal stromal cells, ex vivo cultured
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT04629833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04629833.